Roche

The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
Fierce Pharma
Thu, 08/10/17 - 06:58 pm
pharma stocks
Merck
Pfizer
AbbVie
Eli Lilly
Bristol-Myers Squibb
GSK
Roche
Sanofi
Bayer
Novo Nordisk
Celgene
Biogen
AstraZeneca
Dermira Commits $135M for Global Rights to Roche Eczema Drug
Xconomy
Tue, 08/8/17 - 11:15 pm
Demira
Roche
eczema
lebrikizumab
As Roche wades biosimilar waters, more competitors circle Herceptin
BioPharma Dive
Wed, 08/2/17 - 09:28 pm
Roche
Herceptin
biosimilars
Amgen
Allergan
ABP 980
Celltrion
CT-P6
FDA advances two more Herceptin biosims—this time from Amgen and Teva—as Roche braces for impact
Fierce Pharma
Mon, 07/31/17 - 09:56 pm
FDA
Herceptin
biosimilars
Roche
Amgen
Teva Pharmaceutical
Allergan
Celltrion
Roche raises 2017 outlook after H1 beat
CNBC
Thu, 07/27/17 - 10:02 am
Roche
earnings
Biotechs Find Strength In Numbers In Treating Multiple Sclerosis
Investors Business Daily
Fri, 07/21/17 - 10:25 am
MS
multiple sclerosis
Roche
Celgene
Novartis
Biogen
ozanimod
Gilenya
Ocrevus
Extavia
Diabetes drugmakers partner with mobile startups to boost patient engagement
Medical Marketing and Media
Fri, 07/21/17 - 10:03 am
diabetes
mobile apps
patients
Novo Nordisk
Glooko
Roche
mySugr
Poor test results for Roche cloud growth prospects
Yahoo/Reuters
Wed, 07/19/17 - 09:54 am
Roche
biosimilars
Rituxan
Herceptin
Avastin
5 Big Pharma Stocks With the Best Drug Pipelines
Motley Fool
Tue, 07/18/17 - 11:32 am
Big Pharma
Roche
AstraZeneca
AbbVie
Gilead Sciences
JNJ
The biosimilar pack is growing around Roche’s all-star trio, looking to rip into a $21B franchise
Endpoints
Wed, 07/12/17 - 10:36 am
Roche
biosimilars
Avastin
Herceptin
ABP 215
Amgen
MYL-14010
Mylan Labs
Rituxan
Shire blasts rival Roche for its “misleading” case for hemophilia trailblazer emicizumab
Motley Fool
Sun, 07/9/17 - 07:39 pm
Shire
Roche
hemophilia
emicizumab
Why Drugmakers Aren’t Sweating the Next Wave of Patent Losses
Bloomberg
Sat, 07/8/17 - 10:18 am
patents
Roche
Sanofi
Eli Lilly
patent cliff
Prescribed Reading: I/O is the only game in town
BioPharma Dive
Sat, 07/8/17 - 10:02 am
immuno-oncology
Celgene
BeiGene
Endo International
Opana ER
Novartis
Orkambi
Vertex Pharmaceuticals
Merck
Bristol-Myers Squibb
Roche
Opdivo
Keytruda
Orencia
Rare-Disease Drugmakers Join in Worries Over GOP Health Overhaul
Bloomberg
Fri, 07/7/17 - 10:31 am
rare disease
healthcare reform
Shire
Jazz Pharmaceuticals
Sanofi
Roche
Biogen
Alexion
Vertex Pharmaceuticals
Sanofi and Alnylam plunge into PhIII with a rival to Roche’s top hemophilia drug
Endpoints
Fri, 07/7/17 - 10:22 am
Sanofi
Alnylam
clinical trials
fitusiran
hemophilia
Roche
emicizumab
Industry paid $8.2B to docs, hospitals last year
BioPharma Dive
Wed, 07/5/17 - 07:27 pm
physicians
physician payments
Roche
Novartis
Pfizer
PTC and Roche report solid data for Spinraza rival
BioPharma Dive
Wed, 07/5/17 - 06:55 pm
PTC Therapeutics
Roche
Spinraza
Biogen
RG7916
SMA
spinal muscular atrophy
Roche buys mySugr diabetes app
Drug Delivery Business News
Sat, 07/1/17 - 09:23 am
Roche
mySugr
mobile apps
diabetes
devices
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
Motley Fool
Fri, 06/30/17 - 11:06 am
prescription data
Sanofi
Lantus
Roche
Herceptin
Avastin
Celgene
Revlimid
JNJ
Merck
Remicade
Biogen
Rituxan
Amgen
Enbrel
Gilead Sciences
Harvoni
AbbVie
Humira
Novartis scores second biosimilar approval in two weeks
BioPharma Dive
Thu, 06/29/17 - 09:43 am
Novartis
biosimilars
Enbrel
Europe
Sandoz
Erelzi
Roche
Rituxan

Pages